# Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix®

> **NCT06184204** · — · COMPLETED · sponsor: **Beker Laboratories** · enrollment: 398 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Trombix® (Rivaroxaban)

## Key facts

- **NCT ID:** NCT06184204
- **Lead sponsor:** Beker Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-18
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-06-22
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184204, "Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06184204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*